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Summary 
In a three-way cross-over study the bioavailability of ce-
furoxime was determined in 12 healthy volunteers after 
oral administration of250 mg as cefuroxime axetil (Elo-
bact®; CAS 64544-07-6) in a plain aqueous suspension 
and as tablets from different batches. The tablet formu-
lations showed nearly identical pharmacokinetic para-
meters and were bioequivalent. The mean maximum se-
rum concentration was 4.7 jug/ml, achieved after 2.1 h. 
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The serum half live was 1.2—1.4 h, the area under the 
serum concentration-time curve was 14.3—14.4 ßg/ml • h 
and the urinary recovery of unchanged cefuroxime was 
54 %. The bioavailability of cefuroxime after administra-
tion of cefuroxime axetil in aqueous suspension was lower, 
but bio-inequivalence was not demonstrated. 
Zusammenfassung 
Vergleichende Untersuchungen zur Bioverfügbarkeit von 
Cefuroximaxetil 
In einem Dreifach-cross-over-Versuch wurde bei 12 gesun-
den Probanden die Bioverfügbarkeit von Cefuroxim nach 
oraler Einnahme von Cefuroximaxetil-Tabletten (Elo-
bact®; CAS 64544-07-6; Wirkstoffgehalt 250 mg) aus zwei 
verschiedenen Chargen bestimmt. Als Referenz diente 
eine wäßrige Suspension von Cefuroximaxetil. Die beiden 
Tablettenformulierungen ergaben nahezu identische phar-
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makokinetische Parameter und erwiesen sich als bioäqui-
valent. Die mittlere maximale Serumkonzentration war 
4,7 ßg/ml und wurde nach 2,1 h erreicht, die Serumhalb-
wertszeit 1,2—1,4 h, die Fläche unter der Serumkonzen-
trations-Zeit-Kurve 14,3—14,4 ßg/ml • h und die Wieder-
Key words: 
1. Introduction 
Cefuroxime axetil (CAS 64544-07-6; see Scheme 1) is the 
acetoxyethyl-ester of cefuroxime, a second generation 
cephalosporin for parenteral use, which is ß-lactamase 
stable (O'Callaghan 1979). After oral administration the 
ester is absorbed from the intestine and during passage 
through the mucosa it is hydrolysed releasing the active 
moiety cefuroxime. 
Cefuroxime Axetil A2-Cefuroxime Axetil 
Cefuroxime A2-Cefuroxime 
Scheme 1: Chemical structure of cefuroxime axetil, cefuroxime and of the 
inactive delta 2-isomer. 
Absorption is enhanced by simultaneous ingestion of 
food, the absolute bioavailability of cefuroxime axetil on 
an empty stomach is 30 %, but when administered with 
food it is up to 60 %. Typical pharmacokinetic parame-
ters after a dose of 250 mg are: peak concentrations in 
plasma of 4.4 ug/ml found after 2—3 h, A U C of 14.9 jig/ 
ml • h and urinary recovery of 50 % (Williams and Hard-
ing 1984, Sommers et al. 1984, Finn et al. 1987). 
In the early development of oral formulations of cefurox-
ime axetil there were reports about varying and sporad-
ically poor bioavailability of the drug (cf. Dürckheimer 
1987). This problem was overcome by the development 
of the RS3-tablet which then was brought into the mar-
ket. The aim of the present study was to compare the 
bioavailability of cefuroxime from two batches of such 
cefuroxime axetil tablets with that from a plain aqueous 
suspension as reference, in order to determine the rela-
tive bioavailability of the tablets and the batch-to-batch 
variation. In addition, the study should serve as a model 
for the bioavailability of cefuroxime axetil after single 
and repeated dosing. 
] ) Elobact®; manufacturer: Cascan GmbH & Co. K G , Wiesba-
den (Fed. Rep. of Germany). 
findung von unverändertem Cefuroxim im Urin 54 % der 
gegebenen Dosis. Die Bioverfügbarkeit von Cefuroxim 
nach Einnahme von Cefuroximaxetil in wäßriger Sus-
pension war niedriger, doch Bioinäquivalenz wurde nicht 
gefunden. 
2. Materials and methods 
2.1. Test medications, reagents and chemicals 
The test medications and analytical standards (cefuroxime. ce-
furoxime axetil and d2-cefuroxime axetil) were obtained from 
Cascan 0. The test medications were as follows: 
A: Cefuroxime axetil, 250 mg amorphous powder, to mix with 
10 ml of flavoured aqueous solution, produced April 1988, 
expiry date April 1990. 
B: Cefuroxime axetil, 250 mg tablets, produced December 1987, 
expiry date December 1989. 
C: Cefuroxime axetil, 250 mg tablets, produced January 1987, 
expiry date December 1988. 
Tetrabutylammonium hydrogensulfate (puriss.) was obtained 
from Fluka, Neu-Ulm (FRG), acetonitrile (HPLC—grade) from 
Baker, Groß-Gerau (FRG), all other chemicals (analytical grade) 
were obtained from E. Merck, Darmstadt (FRG). Water was pu-
rified by a Mil l i -Q water purification system (Millipore. Esch-
born, FRG). 
2.2. Volunteers, drug administration and sampling 
Twelve volunteers (6 m, 6 f) aged 20—40 years (median 29 
years), with a weight of 48—86 kg (median 68 kg) and height of 
154—191 cm (median 174 cm) took part in the study. They were 
healthy as judged from medical history, physical examination 
and biochemical tests. The protocol was checked and approved 
by an ethics committee, and written consent was obtained. The 
volunteers fasted 12 h prior to each study day and had a stan-
dardized breakfast at about 7:00 a.m., consisting of two slices of 
toast, 50 g jam, 25 g butter and 250 ml fruit tea. 30 min later, 15 
min after the end of the breakfast, each volunteer took orally one 
of the three presentations of 250 mg cefuroxime axetil together 
with 200 ml water according to a randomized open three-way 
cross-over schedule. Venous blood was taken through an in-
dwelling venous catheter placed in an arm vein, before dosing 
and 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8 and 10 h thereafter. 
The blood was centrifuged at 4 °C, and the serum separated. 
Urine was collected before drug administration and up to 24 h 
thereafter. The specimens were stored frozen at —70 °C until 
analysis. 
2.3. HPLC assay 
Plasma and urine were assayed by high-performance liquid chro-
matography (HPLC) with a modified published procedure (Kees 
et al. 1990 and references, therein). In brief, 200 fil serum were 
mixed with 200 ul 0.2 % acetic acid and 400 ul acetonitrile. The 
precipitated protein was removed by centrifugation, and the ace-
tonitrile was extracted into 2 ml dichloromethane. After centri-
fugation 50 ul of the aqueous supernatant was injected into the 
HPLC-column. Urine was centrifuged diluted 1 : 20 with mobile 
phase (omitting acetonitrile) and 10 ul was injected directly. For 
separation a Hyperchrome® column (i.d. 250 x 4 mm) was used 
filled with Nucleosil CI 8 5 urn obtained from Bischoff. Leonberg 
(FRG). 
The mobile phase was 1000 ml water, 2.5 g tetrabutylammonium 
hydrogen sulfate, 600 ul acetic acid, 450 ml acetonitrile. pH 4.75 
with 10 mol/1 sodium hydroxide. The eluent was monitored by 
a photometric detector set at 275 nm. At a flow rate of 1 ml/min 
(30 °C) the retention time of cefuroxime was 5.8 min and that of 
the inactive delta 2-isomer 6.3 min. The retention times of ce-
furoxime axetil diastereomers were 14.6 and 16.2 min. Recovery 
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of cefuroxime from serum was quantitative, the limit of quan-
titation of cefuroxime was 50 ng/ml in serum and 10 ug/ml in 
urine. 
2.4. Pharmacokinetic calculations 
The pharmacokinetic parameters were calculated from the 
plasma concentrations of cefuroxime for each subject. The max-
imum serum concentration (C m ? x ) and the time to reach C m a x 
Umax) were determined by visual inspection of the serum concen-
tration versus time data. The elimination constant (ke l) and the 
serum half life (ti/2) were calculated by linear regression (log-lin 
scale) of the concentrations in the elimination phase. The area 
under the curve (AUC) was calculated by the trapezoidal rule 
(linear scale). The extrapolation from the last measured point to 
infinity was obtained by dividing the concentration of the last 
measured point by the elimination constant. The percentage of 
the dose administered which was recovered in the urine 
( U 0 _ 2 4 h) w ^s calculated from the concentration in the 24-h urine 
collection multiplied by the volume of the urine. 
2.5. Statistical evaluation 
The following parameters were tested statistically using the 
Student t-test (a = 0.05): U 0 _ 2 4 h , t i / 2 , C m „ , t m a x , A U C 0 _ 1 0 h , 
AUCo_.o. For determination of bioequivalence the individual 
quotients of C m a x and A U Q - ^ after administration of the test 
substances and the reference substance were calculated. The 
90 % confidence interval (see Blume and Mutschler, 1989) was 
calculated using a computer programme (PC-version of BIOQ, 
Steinijans and Diletti, 1983 a, b, obtained from: Zentrallabora-
torium Deutscher Apotheker, Eschborn, FRG). 
3. Results 
3.1. Pharmacokinetic parameters 
The mean serum concentrations are shown in Fig. 1 and 
the derived pharmacokinetic parameters in Table 1. Very 
similar pharmacokinetic parameters (mean ± standard 
deviation) were found for both batches of tablets; the 
mean serum half life of cefuroxime was 1.36 ± 0.38 h 
(B) and 1.24 ±0.19 h (C), the maximum serum concen-
tration C m a x was 4.76 ± 1.20 ug/ml (B) and 4.69 ± 1.58 
Hg/ml (C) and t m a x 2.13 ± 0.74 h and 2.13 ± 0.48 h. The 
A U C Q - ^ was 14.4 ± 2.8 (B) and 14.3 ± 3.1 ug/ml • h, 
and the urinary recovery 53.8 ± 7.8 % and 53.7 ± 6.1 % 
of the administered dose. In the latter case the urine data 
of one subject was not included as a portion of the urine 
was lost. Serum half-life (1.27 ± 0.12 h) and the time to 
reach maximum serum concentration (2.00 ± 0.43 h) 
were the same after administration of the aqueous sus-
pension with respect to the tablets, but C m a x itself 
(3.85 ± 1.55 |ig/ml), AUC 0 _« (12.3 ± 3.8 ug/ml • h)and 
urinary recovery (42.8 ± 1 0 . 1 %) were lower with the 
aqueous suspension, in the latter case statistically signif-
icant. 
Bioequivalence was demonstrated for both batches of 
tablets (Table 2), but not between tablets and aqueous 
suspension, where appearance of cefuroxime in serum 
was earlier, although mean bioavailability was lower as 
measured by A U C and urinary recovery. 
3.2. Tolerance 
Al l medications were well tolerated, and not gastrointes-
tinal or allergic side-effects were registered, only head-
ache was reported in two cases 7—8 h after administra-
tion. The volunteers were allowed to take a mild analgesic 
after 10 h. Headache is not a recognized side-effect of 
orally administered cephalosporins and in this case may 
have been due to study conditions, i.e. getting up early 
and avoiding morning-coffee. 
4. Discussion 
In the present bioavailability study the two batches of 
cefuroxime axetil tablets appeared bioequivalent. The 
serum concentration (ug/ml) 
5 l 
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Fig. 1: Mean serum concentration of cefuroxime after oral administration 
of 250 mg cefuroxime as axetil in 12 healthy volunteers. A = plain aqueous 
suspension; B = tablet, produced December 1987: C = tablet, produced 
January 1987. 
Table 1: Pharmacokinetic parameters (mean; standard deviation; coeffi-
cient of variation) of cefuroxime in 12 healthy volunteers after oral admi-
nistration of 250 mg cefuroxime as axetil. 
Parameter Dimension A B C 
c m a x 
T m a x 
ti/2 
A U C Q _ . 
U 0 -2 ,h 
jig/ml 
h 
h 
ug/ml • h 
% of dose 
3.85±1.55 (40) 
2.00±0.43 (22) 
1.2710.12(09) 
1 2 . 4 ± 3 . 8 ( 3 1 ) 
42.8110.1 (24) 
4.7611.20 (25) 
2.1310.74 (35) 
1.3610.38 (28) 
14.412.8(19) 
53.817.8 (14) 
4.6911.58 (34) 
2.1310.48 (23) 
1.2410.19(15) 
14.313.1 (22) 
53.716.1 (11);" 
a ) Mean of 11 as in one subject (recovery 9.3 %) part of urine was lost. 
Table 2: Test for bioequivalence (test/reference, Wilcoxon test) of three for-
mulations of cefuroxime axetil. 
Parameter 
B / A C7A C / B 
p.e. 90% p.e. 90% p.e. 90% 
r 
'•—max 
A U C 0 _ 
126.5 
118.5 
112.6-142.9 
106.8-131.1 
124.3 
117.7 
112.2-138.6 
105.6-128.8 
98.4 
98.9 
89.6-105.4 
96.2-101.4 
A = plain aqueous suspension; B = tablet, produced December 1987; C = 
tablet, produced January 1987; abbr.: p.e. = point estimator; 90 % = 90 % 
confidence interval. 
peak serum concentration of 4.7 ug/ml corresponds to the 
levels found by other investigators (Williams and Hard-
ing 1984, Sommers et al. 1984, Finn et al. 1987) and, after 
dose correction, they are higher than maximum serum 
concentrations of other new oral cephalosporins such as 
Cefixime (Kees et al. 1987, 1990; review: Brogden and 
Campoli-Richards 1989) and Cefetamet pivoxyl (review: 
Stoeckel et al. 1989). Compared with cefotiam hexetil 
(Couet et al. 1987, Deppermann et al. 1989) the area un-
der the serum concentration-time curve was also higher. 
In addition, this three-way cross-over study provides a 
good model for the absorption of cefuroxime axetil after 
single and repeated dosing, and the results show that ce-
furoxime axetil is reliably and reproducibly absorbed. 
High serum concentration of cefuroxime was achieved 
more rapidly following administration of the aqueous 
suspension, compared with the tablet formulations, al-
though maximum serum concentrations and area under 
the curve were lower. This was surprising since the use of 
a solution or an aqueous suspension in determination of 
the relative bioavailability of oral formulations is based 
on the assumption that it is better absorbed than other 
formulations (cf. results with older cephalosporins of the 
cephalexin type, Riess et al. 1982). 
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Increased bioavailability following postprandial admin-
istration of cefuroxime axetil compared to administra-
tion in the fasting state has been demonstrated in previ-
ous studies (Sommers et al. 1984, Williams et al. 1984, 
Finn et al. 1987), and similar results have been obtained 
with other ester prodrug cephalosporins (Stoeckel et al. 
1989, Deppermann et al. 1989). Rapid gastric emptying 
in the fasting state possibly results in an exessive amount 
of cephalosporin presented to the upper small intestine, 
saturating the absorption process (leading presumably to 
zero-order absorption kinetics, cf. Hespe et al. 1987), 
thereby having a negative effect on bioavailability. The 
absolute bioavailability of all newer oral ester prodrug 
cephalosporins, including the carboxymethyl cephalo-
sporins are below 50—60 % (Dürckheimer et al. 1987) 
which suggests an absorption mechanism through the 
mucosa with limited capacity. 
It has been postulated that a carrier mediated transport 
mechanism is involved in the absorption of ß-lactam an-
tibiotics (Iseki et al. 1989, and references therein; Mur-
anashi et al. 1987, Okano et al. 1987, Tamai et al. 1987; 
Tsuji et al. 1987) and that it is similar to that involved 
in the absorption of dipeptides from the small intestine 
(Kramer 1987, Kramer et al. 1988). Alternatively absorp-
tion may be by passive diffusion, where lipophilicity is 
the rate limiting factor (Sugawara et al. 1990). This mech-
anism has been discussed in relation to amoxicillin 
(Hespe et al. 1987), assumed for Cefetamet pivoxyl 
(Stoeckel et al. 1989), and for cefuroxime axetil is an at-
tractive alternative to the carrier transport theory. The 
optimal conditions for absorption of ester prodrug ceph-
alosporins are found in the duodenum and the upper part 
of the small intestine, where pH is in the range of 4 to 6. 
The water solubility (i.e. low lipophilicity) of ester prod-
rug cephalosporins is highest at low pH values in the 
stomach (Stoeckel et al. 1989), and reduces at higher pH. 
However, increasing the pH above 7 leads to isomeriza-
tion and inactivation of ester prodrug cephalosporins 
and/or hydrolysis to the non-absorbable parent cephalo-
sporins (Miyauchi et al. 1989a, b). For cefuroxime axetil 
in-vitro isomerization to the inactive delta 2-isomer and 
hydrolysis to delta 2-cefuroxime have been observed 
(Ayrton 1986), but not to any appreciable degree in-vivo. 
From the lack of gastrointestinal side effect in this study 
we assume that active cefuroxime which could impair the 
natural bacterial flora is not liberated in the gut lumen, 
and that isomerisation of non-absorbed cefuroxime axetil 
to delta 2-cefuroxime axetil is the dominating process in 
the deeper parts of the small intestine. 
The urinary recovery rate of 54 % of the administered 
dose indicates an absolute bioavailability of 60 %: this is 
lower than that for the older cephalosporins of the ce-
phalexin type which are almost totally absorbed and to-
tally excreted in the urine (review by Riess et al. 1982). 
On the other hand, urinary recoveries of oral penicillins 
which are generally considered to have good absorption, 
e.g. amoxicillin or bacampicillin, are also only about 
50 % (cf. Blume and Mutschler 1989), and are less well 
absorbed when administered after food (Sommers et al. 
1984), indicating and absolute bioavailability signifi-
cantly lower than 100 %. 
In conclusion, this study demonstrated the bioequival-
ence of the two batches of cefuroxime axetil tablets and 
the reliable absorption of cefuroxime axetil, and that ab-
sorption of the aqueous suspension was slightly lower 
than that of the tablets. 
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